Finance

Lists
B1SX34:BVMF
Boston Scientific Corp Brazilian Depositary Receipt
53,34 R$
0,00%
(0,00) 1D
9 қаз., 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for B1SX34...
Open
52,72 R$
High
53,34 R$
Low
52,50 R$
Mkt. cap
63,53 млрд
Avg. vol.
1,02 мың
Volume
67,00
52-wk high
140,91 R$
52-wk low
50,29 R$
Shares outstanding
1,45 млрд
No. of employees
59 мың
Open
52,72 R$
High
53,34 R$
Low
52,50 R$
Mkt. cap
63,53 млрд
Avg. vol.
1,02 мың
Volume
67,00
52-wk high
140,91 R$
52-wk low
50,29 R$
Shares outstanding
1,45 млрд
No. of employees
59 мың
News stories
From web sources and news partners
Profile
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
About Boston Scientific Corp Brazilian Depositary Receipt
CEOMichael F. Mahoney
Employees59 мың
Founded1979 ж. 29 мау.
HeadquartersМарлборо, Массачусетс, Америка Құрама Штаттары
SectorMedical device
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
5,06 млрд
5,29 млрд
5,20 млрд
5,44 млрд
Cost of goods sold
1,54 млрд
1,61 млрд
1,60 млрд
1,61 млрд
Cost of revenue
1,54 млрд
1,61 млрд
1,60 млрд
1,61 млрд
Research and development expenses
514,00 млн
569,00 млн
516,00 млн
554,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,74 млрд
1,83 млрд
1,78 млрд
1,80 млрд
Operating expense
2,48 млрд
2,63 млрд
2,53 млрд
2,59 млрд
Total operating expenses
4,02 млрд
4,24 млрд
4,13 млрд
4,20 млрд
Operating income
1,05 млрд
1,04 млрд
1,07 млрд
1,25 млрд
Other non operating income
-16,00 млн
28,00 млн
28,00 млн
-6,00 млн
EBT including unusual items
938,00 млн
700,00 млн
1,16 млрд
1,06 млрд
EBT excluding unusual items
935,00 млн
1,01 млрд
999,00 млн
1,14 млрд
Income tax expense
183,00 млн
30,00 млн
-176,00 млн
155,00 млн
Effective tax rate
19,51%
4,29%
-15,13%
14,62%
Other operating expenses
-
-
-
-
Net income
755,00 млн
672,00 млн
1,34 млрд
907,00 млн
Net profit margin
14,91%
12,71%
25,77%
16,67%
Earnings per share
0,75
0,80
0,80
0,86
Interest and investment income
-
29,00 млн
-
11,00 млн
Interest expense
-87,00 млн
-90,00 млн
-90,00 млн
-96,00 млн
Net interest expenses
-87,00 млн
-61,00 млн
-90,00 млн
-85,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,39 млрд
1,41 млрд
1,42 млрд
1,60 млрд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары